.jpg)
MeRT®
(Magnetic e-Resonance Therapy) is an FDA-cleared, EEG-guided neuromodulation treatment. It measures each patient's individual brainwave activity before personalising a stimulation protocol, offered at Aurora Life as an adjunctive approach for adults living with PTSD.
For many people, the traumatic event itself is long over. Time has passed, the environment has changed, and life has moved forward. Yet the brain may still respond as though the danger remains: sleep becomes lighter, concentration becomes harder, and ordinary situations can feel unexpectedly overwhelming.
The nervous system stays on high alert, even in moments of complete safety. This is one of the defining characteristics of Post-Traumatic Stress Disorder (PTSD). It is not a sign of weakness, nor simply an inability to “move on”, it reflects measurable changes in how the brain processes threat, memory and emotion.
One of the most common misconceptions about PTSD is that it exists only in our memories. Modern neuroscience tells a more complex story.
A traumatic event can influence how different brain networks communicate with one another, affecting emotional regulation, attention, memory and the perception of safety. Rather than returning to its normal resting state once danger has passed, the brain can remain locked in patterns that keep it prepared for a threat that no longer exists.
Among the networks receiving growing scientific attention is the Default Mode Network (DMN), which is most active when the brain is at rest and plays an important role in self-reflection, autobiographical memory and our internal dialogue.
In individuals living with PTSD, this network is often dysregulated. Instead of shifting naturally between rest and focused attention, its activity and connectivity can become disrupted, contributing to symptoms such as:
- Intrusive memories
- Rumination
- Flashbacks
- Emotional distress
- Difficulty feeling mentally at rest
Rather than allowing the traumatic experience to become part of the past, these altered patterns may contribute to the brain repeatedly revisiting it.
For decades, PTSD treatment has primarily relied on psychotherapy and medication. These remain essential components of care and have helped millions of people around the world. But growing research points to an important reality: PTSD does not affect every brain in the same way.
The severity of symptoms, the underlying brain activity, and an individual's response to treatment can vary considerably from person to person, which raises an important question. If every brain is different, treatment should be different too.
This is the principle behind MeRT® (Magnetic e-Resonance Therapy). Rather than relying on symptoms alone, MeRT begins by measuring each patient's individual brain activity. Using quantitative electroencephalography (qEEG) together with an electrocardiogram (ECG), clinicians record how the brain and heart are functioning while the patient is at rest.
This data is then analysed to identify measurable patterns in brainwave activity and synchrony, providing an objective baseline that helps clinicians personalise the stimulation protocol for each individual. Rather than applying identical treatment settings to every patient, MeRT draws on each person's own neurophysiological data to help guide their care: an approach that reflects a broader shift taking place across medicine, from standardised treatment towards precision medicine.
In June 2026, the U.S. Food and Drug Administration (FDA) granted clearance for the MeRT® System as an adjunctive treatment for adults living with PTSD. The clearance followed a multicentre, randomised, double-blind clinical trial evaluating personalised EEG-guided neuromodulation, in which, according to the FDA's published review, participants receiving MeRT experienced an average 52% reduction in PTSD symptom severity during the study.
While no single therapy is appropriate for every individual, this milestone represents an important step towards more personalised approaches to mental healthcare. It also reflects a broader movement within neuroscience: understanding that objective measurements of brain function may help clinicians tailor treatment more precisely to the individual sitting in front of them.
At Aurora Life, we believe the future of medicine begins with understanding biology before disease demands attention. The same philosophy that guides precision longevity medicine also applies to the brain: measure first, understand the individual, then personalise care.
As our understanding of brain health continues to evolve, technologies such as MeRT represent an important step towards a future where treatment is informed not only by symptoms, but by the biology that underlies them.
Because no two brains are exactly alike.
Care should be built the same way.
SOURCES
• U.S. Food and Drug Administration. 510(k) Summary: MeRT® System (K260402), June 2026.
• McGovern Medical School, University of Texas Health Science Center at Houston. MeRT Receives FDA Clearance for PTSD: A New Step Toward Personalized Neuromodulation (July 2026).
• Wave Neuroscience. MeRT® System and clinical resources.
• Shiner B. et al. Journal of Clinical Psychiatry (2020).
• McGeary D.D. et al. JAMA Neurology (2022).
What is MeRT therapy?
MeRT® (Magnetic e-Resonance Therapy) is a form ofEEG-guided neuromodulation. Rather than applying a standard protocol to everypatient, it measures each individual's brainwave activity and heart rhythmfirst, then personalises the treatment based on that data.
Is MeRT FDA-cleared for PTSD?
Yes. In June 2026, the FDA granted clearance for theMeRT® System as an adjunctive treatment for adults living with PTSD, followinga multicentre, randomised, double-blind clinical trial.
How is MeRT different fromstandard PTSD treatment?
Standard PTSD care relies primarily on psychotherapy andmedication, applied in largely similar ways across patients. MeRT insteadbegins by measuring each patient's individual brain activity via qEEG and ECG,then uses that data to personalise the stimulation protocol for that person.
Does MeRT replace psychotherapyor medication for PTSD?
No. MeRT is intended as an adjunctive treatment, used along side, not in place of, established approaches such as psychotherapy andmedication.
By submitting this form, you consent receiving marketing messages from Aurora Life.
